Phase 2 Pancreatic Cancer Trial, Recruiting NCT06922591 Sponsor: Tango Therapeutics, Inc. Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT06922591
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older at the time of signing the consent form
  • Your general health and ability to carry out daily activities is rated at a good or mostly good level (what doctors call ECOG performance status 0 or 1 — confirm with trial site)
  • Your tumor has a specific genetic or protein change involving something called MTAP (confirm with trial site for testing details)
  • For some parts of the trial (Arms A and B only): your tumor has a specific gene change called a RAS mutation
  • You have been diagnosed with advanced pancreatic cancer (PDAC) or advanced or returning non-small cell lung cancer (NSCLC) that has been confirmed by a tissue test
  • You have already received standard cancer treatment before joining this trial
  • For some parts of the trial (Arms A and B only): you have NOT previously received any treatment that specifically targets the RAS gene
  • You have measurable disease, meaning your tumor can be seen and measured on scans
  • Your organs (such as kidneys, liver, and bone marrow) are working well enough to participate
  • You are able to swallow tablets
  • If you could become pregnant, you have a negative pregnancy test at the time of screening
  • You are willing and able to give written consent to participate

Who may not be able to join:

  • You have previously been treated with a type of drug called a PRMT5 inhibitor or MAT2A inhibitor
  • For some parts of the trial (Arms A and B only): you have previously taken part in a Phase 3 clinical trial of RMC-6236 or RMC-9805
  • You have a known allergy or bad reaction to any of the study drugs used in this trial or their ingredients
  • You have another serious illness that is not well controlled and could make it hard to follow the study requirements
  • You currently have an active infection that requires treatment with systemic medicines (medicines that work throughout the whole body)
  • You are currently in another clinical trial or plan to join one at the same time as this trial
  • You have a condition affecting your digestive system that could stop your body from properly absorbing the oral (swallowed) medications in the trial
  • You have known or suspected cancer that has spread to the brain or spinal cord and is causing new or worsening symptoms
  • You currently have active liver disease of any kind
  • You are HIV positive, unless your immune cell count and viral levels are well controlled and you are on effective HIV treatment (confirm specific requirements with trial site)
  • You have significant heart or blood vessel (cardiovascular) disease (confirm with trial site)
  • You have a history of, or currently have, a lung condition called interstitial lung disease
  • You are pregnant or currently breastfeeding
  • You are unwilling or unable to attend scheduled visits, take the study treatment as planned, or follow other study requirements
  • You have any other significant past or current health condition that, in the doctor's opinion, could affect your safety or make it hard to evaluate the results of the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Maxim Pimpkin, MD, PhD, Tango Therapeutics, Inc.

Phone: 857-320-4899

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Tango Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
31 May 2025
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Phase 1: Maximum Tolerated Dose; Phase 1: Maximum Tolerated Dose; Phase 2: Combination Anti-neoplastic Activity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov